1-Iodo-3-pentylbenzene | 1359844-18-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Iodo-3-pentylbenzene
• CAS: 1359844-18-0
• 化学式: C₁₁H₁₅I
• 分子量: 274.145
• InChiKey: UUJAIINOGJSZEY-UHFFFAOYSA-N

物化性质

• 沸点：
  282.7±19.0 °C(Predicted)
• 密度：
  1.414±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-Iodo-3-pentylbenzene 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium hydrogen fluoride 、 palladium diacetate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 0.5h， 生成 Potassium;trifluoro-(3-pentylphenyl)boranuide
  参考文献：
  名称：

  Design and synthesis of boronic acid inhibitors of endothelial lipase

  摘要：

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.043
• 作为产物：
  描述：

  3-nitrophenyl trifluoromethanesulfonate 在 2-双环己基膦-2',6'-二甲氧基联苯 、 盐酸 、 potassium phosphate monohydrate 、 palladium on activated charcoal 、 氢气 、 palladium diacetate 、 sodium nitrite 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 生成 1-Iodo-3-pentylbenzene
  参考文献：
  名称：

  Design and synthesis of boronic acid inhibitors of endothelial lipase

  摘要：

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.043

文献信息

• Antifungal and antiparasitic indoloquinoline derivates
  申请人：Ablordeppey Y. Seth

  公开号：US20070232640A1

  公开（公告）日：2007-10-04

  A compound having the formula: wherein: R is an electron withdrawing or electron donating moiety; R 5 and R 10 may be the same or different and are a straight or branched 1-5 carbon or heteroatom chain substituted terminally by a cycloalkyl or aromatic ring, or other structural isomer or complex thereof; n is the position of substitution of R; Z is N—R 10 , O, S, S═O, CH 2 or C═O; y is 1-5 and Q is Z or NH, with the proviso that, where Z is NH, N—CH 3 , S or O and R n is H, R 5 may not be CH 3 ; as well as quaternary ammonium salts thereof and their use as pharmacological compositions and for methods of treatment.

  具有以下化学式的化合物： 其中：R是一个电子受体或电子给予基团； R5和R10可以相同也可以不同，是一条直链或支链的1-5碳或杂原子链，在末端被环烷基或芳香环取代，或其他结构异构体或其复合物；n是R的取代位置； Z是N—R10，O，S，S═O，CH2或C═O；y为1-5，Q为Z或NH， 但是，如果Z为NH，N—CH3，S或O，且Rn为H，则R5可能不是 ；以及其季铵盐和它们作为药物组合物的用途和治疗方法。
• Antifungal and Antiparasitic Indoloquinoline Derivatives
  申请人：Ablordeppey Seth Y.

  公开号：US20120157493A1

  公开（公告）日：2012-06-21

  “An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring; the 10 position is N—R 10 , O, S, S═O, CH 2 , or C═O, where R 10 is a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring. In one embodiment the quarternary N-5 atom is —CH 3 and the 10 position is N—(CH 2 ) 5 -Ph.”

  “一种吲哚喹啉，其中季铵N-5原子是直链C（1-5）链，分支C（1-5）链，杂原子链，末端被环烷基或芳香环取代的直链，末端被环烷基或芳香环取代的分支链，末端被环烷基或芳香环取代的杂原子链; 10位是N-R10，O，S，S═O，CH2或C═O，其中R10是分支C（1-5）链，杂原子链，末端被环烷基或芳香环取代的直链，末端被环烷基或芳香环取代的分支链，末端被环烷基或芳香环取代的杂原子链。在一种实施例中，季铵N-5原子是-CH3，而10位是N-（ ）5-Ph。”
• SPHINGAMIDE COMPOUNDS AND METHODS FOR BINDING INKT CELLS
  申请人：La Jolla Institute for Allergy and Immunology

  公开号：EP3374028B1

  公开（公告）日：2021-05-26
• US8158646B2
  申请人：——

  公开号：US8158646B2

  公开（公告）日：2012-04-17
• US8703798B2
  申请人：——

  公开号：US8703798B2

  公开（公告）日：2014-04-22